The Trump administration's move to end subsidies for Medicare drug plans could cost consumers

The Trump administration has announced the early termination of federal subsidies designed to stabilize Medicare Part D premiums, a move that could lead to significant cost increases for millions of beneficiaries in 2027. These subsidies were initially implemented to help insurers transition to new cost-sharing structures mandated by the Inflation Reduction Act, which capped annual out-of-pocket drug spending at $2,000. For the pharmaceutical sector, this shift signals a change in the federal support landscape for drug coverage and may influence how insurers price plans and manage medication access for seniors.

Dr. Mehmet Oz, who oversees the Centers for Medicare and Medicaid Services (CMS), announced the termination of the premium stabilization subsidies via the social media platform X, characterizing the billions in federal payments to insurance companies as unacceptable. These subsidies were originally established by the Biden administration as a temporary demonstration project to help insurers adjust to the Inflation Reduction Act of 2022, which capped out-of-pocket drug spending for Medicare patients at $2,000. While the program was intended to last through 2027, the Trump administration is ending it a year early, potentially exposing millions of beneficiaries to higher premiums as insurers take on a larger share of drug costs.

The financial scale of the subsidies is significant, with the Government Accountability Office (GAO) estimating a cost of $9.8 billion for 2025 and 2026. Approximately 23 million people were enrolled in standalone Medicare Part D drug plans in 2025 and benefited from this financial stabilization. Juliette Cubanski, a vice president at KFF, noted that these subsidies reduced average drug plan premiums by $16 this year, a substantial amount given that the current average premium for standalone drug coverage is $36. Without this federal support, beneficiaries could have faced premium increases of nearly 50% to maintain their existing coverage levels.

Industry experts express concern that the removal of these subsidies will disproportionately impact traditional Medicare beneficiaries who rely on standalone drug plans rather than Medicare Advantage plans. Stacie Dusetzina, a professor at Vanderbilt University School of Medicine, observed that Medicare Advantage plans often have more flexibility to keep premiums low, and the subsidy removal may accelerate a shift toward these private alternatives. This migration could have long-term implications for the pharmaceutical sector, as Medicare Advantage plans often utilize more limited provider networks and different management strategies for expensive prescription drugs. Patients may be forced to choose between higher premiums in traditional Medicare or the restricted access associated with Advantage plans.